Laurus Labs growth over the years

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Compounded a year1 yr3 yr
Revenue+22.7%+4.1%
EBITDA+68.5%+3.7%
Net Income+148.6%+3.9%
EPS (adj.)+148.2%+4.0%
Total Assets+12.6%+11.1%
Total Equity+18.0%+10.3%
Free Cash Flow—+428.8%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

LAURUSLABS₹2,181.90

Laurus Labs Ltd.

· Pharma & Health
₹ CrorePeersDIVISLABGLANDMANKINDBIOCONALKEMLUPINFORTISGLENMARKMcap ₹1.18L Cr
Annuals · FY-end closes
Compounded Growth
Annuals · CAGR %
1Y
CAGR
3Y
CAGR
Revenue+22.7+4.1
EBITDA+68.5+3.7
Net Income+148.6+3.9
EPS (adj.)+148.2+4.0
Total Assets+12.6+11.1
Total Equity+18.0+10.3
Free Cash Flow—+428.8
CAGR from filed annuals — needs positive start & end values.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.